http://www.ipharminc.com/press-release daily 0.75 2023-08-27 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477576112838-0FSI1GSU4FIK7IN8YKFT/image-asset.jpeg Press Releases http://www.ipharminc.com/press-release/2023/8/27/innovation-pharmaceuticals-announces-new-milestone-at-beamed-on-track-to-file-510k-submission-to-fda-in-q2-2024 monthly 0.5 2023-08-28 http://www.ipharminc.com/press-release/2023/6/21/innovation-pharmaceuticals-provides-update-on-us-patent-applications-covering-use-of-brilacidin-in-inflammatory-bowel-diseases-coronaviruses-and-fungal-diseases monthly 0.5 2023-06-21 http://www.ipharminc.com/press-release/2023/6/5/innovation-pharma-announces-beamed-technologies-breakthrough-in-development-of-fiber-optic-probes-for-stingray-laser-system-paves-way-for-groundbreaking-integration-testing monthly 0.5 2023-06-05 http://www.ipharminc.com/press-release/2023/4/17/innovation-pharmaceuticals-brilacidin-antifungal-research-published-in-nature-communications monthly 0.5 2023-04-17 http://www.ipharminc.com/press-release/2023/3/15/innovation-pharmaceuticals-announces-new-antifungal-testing-of-brilacidin-by-nihniaid-affiliated-and-other-academic-researchers monthly 0.5 2023-03-15 http://www.ipharminc.com/press-release/2023/2/23/innovation-pharmaceuticals-visits-beamed-new-stingray-laser-system-for-epilepsy-and-brain-tumors-moving-toward-fda-submission monthly 0.5 2023-02-23 http://www.ipharminc.com/press-release/2023/1/9/innovation-pharmaceuticals-announces-bt-beamedical-technologies-and-shina-systems-ltd-enter-into-a-definitive-strategic-development-agreement monthly 0.5 2023-02-22 http://www.ipharminc.com/press-release/2022/12/13/innovation-pharmaceuticals-reports-new-in-vivo-antifungal-data-showing-brilacidins-potential-for-treating-fungal-keratitis monthly 0.5 2022-12-13 http://www.ipharminc.com/press-release/2022/11/28/innovation-pharmaceuticals-announces-bt-beamedical-technologies-receives-fda-clearance-for-new-surgical-laser-family monthly 0.5 2022-11-28 http://www.ipharminc.com/press-release/2022/11/15/scientific-poster-on-innovation-pharmaceuticals-brilacidin-to-be-presented-at-2022-chemical-and-biological-defense-science-amp-technology-conference monthly 0.5 2022-11-15 http://www.ipharminc.com/press-release/2022/10/26/nhs-medical-director-for-specialised-services-calls-new-laser-technology-for-epilepsy-game-changing-breakthrough monthly 0.5 2022-10-26 http://www.ipharminc.com/press-release/2022/10/3/innovation-pharmaceuticals-announces-publication-of-scientific-article-on-the-antifungal-activity-of-brilacidin monthly 0.5 2022-10-04 http://www.ipharminc.com/press-release/2022/9/14/new-in-vitro-data-supporting-the-broad-spectrum-antiviral-activity-of-innovation-pharmaceuticals-brilacidin-presented-at-2022-military-health-system-research-symposium monthly 0.5 2022-09-15 http://www.ipharminc.com/press-release/2022/9/12/innovation-pharmaceuticals-investment-in-bt-beamedical-helping-advance-new-surgical-laser-platform monthly 0.5 2022-09-13 http://www.ipharminc.com/press-release/2022/8/5/innovation-pharmaceuticals-announces-nihniaid-affiliated-researchers-to-evaluate-brilacidins-treatment-potential-against-monkeypox monthly 0.5 2022-08-05 http://www.ipharminc.com/press-release/2022/7/22/provider-and-payer-analysis-supports-potential-commercialization-of-innovation-pharmaceuticals-brilacidin-as-a-novel-oral-mucositis-drug-candidate monthly 0.5 2022-08-05 http://www.ipharminc.com/press-release/2022/6/28/innovation-pharmaceuticals-announces-new-antiviral-research-on-brilacidin-in-bunyaviruses-and-alphaviruses-to-be-presented-at-the-2022-military-health-system-research-symposium monthly 0.5 2022-06-28 http://www.ipharminc.com/press-release/2022/6/23/innovation-pharmaceuticals-reports-brilacidin-inhibits-omicron-delta-gamma-and-alpha-sars-cov-2-variants-based-on-in-vitro-testing-by-nihniaid-sponsored-and-rutgers-university-researchers monthly 0.5 2022-06-23 http://www.ipharminc.com/press-release/2022/6/15/innovation-pharmaceuticals-acquires-stake-in-squalus-medical-seeks-to-reshape-cancer-and-epilepsy-treatments-through-a-new-image-guided-laser-based-ablation-technology monthly 0.5 2022-06-15 http://www.ipharminc.com/press-release/2022/3/15/innovation-pharmaceuticals-announces-publication-of-peer-review-article-in-the-journal-of-medical-virology-on-anti-coronavirus-properties-of-brilacidin monthly 0.5 2022-08-05 http://www.ipharminc.com/press-release/2022/3/7/innovation-pharmaceuticals-reports-additional-findings-based-on-review-of-brilacidin-phase-2-covid-19-trial-results-and-compassionate-use-cases monthly 0.5 2022-04-11 http://www.ipharminc.com/press-release/2021/12/7/innovation-pharmaceuticals-analyzing-full-dataset-for-its-brilacidin-covid-19-clinical-trial-company-evaluating-new-pipeline-opportunities-for-2022 monthly 0.5 2021-12-07 http://www.ipharminc.com/press-release/2021/11/18/innovation-pharmaceuticals-provides-brilacidin-program-update monthly 0.5 2021-11-18 http://www.ipharminc.com/press-release/2021/11/12/innovation-pharmaceuticals-conducting-full-data-analysis-of-phase-2-brilacidin-covid-19-trial-results-to-support-brilacidins-potential-inclusion-in-government-sponsored-covid-19-trials monthly 0.5 2021-11-12 http://www.ipharminc.com/press-release/2021/11/11/innovation-pharmaceuticals-announces-topline-results-from-phase-2-clinical-trial-of-brilacidin-for-covid-19 monthly 0.5 2021-11-11 http://www.ipharminc.com/press-release/2021/11/3/database-lock-completed-for-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19 monthly 0.5 2021-11-03 http://www.ipharminc.com/press-release/2021/10/25/innovation-pharmaceuticals-covid-19-clinical-trial-topline-results-anticipated-to-be-reported-the-week-of-november-8th monthly 0.5 2021-10-25 http://www.ipharminc.com/press-release/2021/9/23/innovation-pharmaceuticals-provides-update-on-covid-19-clinical-trial-compassionate-use-requests-and-research-into-brilacidins-broad-spectrum-antiviral-properties monthly 0.5 2022-08-05 http://www.ipharminc.com/press-release/2021/8/12/last-patient-last-visit-completed-in-innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-covid-19-trial-database-undergoing-review-in-preparation-for-database-lock monthly 0.5 2021-08-12 http://www.ipharminc.com/press-release/2021/8/2/innovation-pharmaceuticals-provides-update-on-brilacidin-antiviral-research monthly 0.5 2021-08-02 http://www.ipharminc.com/press-release/2021/7/22/innovation-pharmaceuticals-announces-new-in-vitro-data-supporting-brilacidins-broad-spectrum-antiviral-potential-presented-at-the-american-society-of-virologys-annual-meeting monthly 0.5 2021-07-22 http://www.ipharminc.com/press-release/2021/6/18/innovation-pharma-announces-new-brilacidin-antiviral-research-on-non-sars-cov-2-endemic-viral-diseases-to-be-presented-at-the-2021-military-health-system-research-symposium monthly 0.5 2022-08-05 http://www.ipharminc.com/press-release/2021/6/3/innovation-pharma-completes-enrollment-in-phase-2-clinical-trial-for-covid-19 monthly 0.5 2021-06-03 http://www.ipharminc.com/press-release/2021/5/27/patient-enrollment-reaches-90-percent-in-innovation-pharmas-phase-2-clinical-trial-of-brilacidin-for-covid-19 monthly 0.5 2021-05-27 http://www.ipharminc.com/press-release/2021/5/13/innovation-pharma-files-form-10-q-patient-enrollment-in-phase-2-clinical-trial-of-brilacidin-for-covid-19-tops-70-percent monthly 0.5 2021-05-13 http://www.ipharminc.com/press-release/2021/4/28/innovation-pharma-surpasses-50-percent-enrollment-in-phase-2-clinical-trial-of-brilacidin-for-covid-19 monthly 0.5 2021-04-28 http://www.ipharminc.com/press-release/2021/4/14/innovation-pharmas-broad-spectrum-antiviral-drug-candidate-brilacidin-highlighted-in-biodefense-and-infectious-diseases-covid-19-presentation monthly 0.5 2021-04-14 http://www.ipharminc.com/press-release/2021/4/7/innovation-pharma-announces-brilacidin-abstract-accepted-for-oral-presentation-at-the-american-society-for-virologys-annual-meeting monthly 0.5 2021-04-07 http://www.ipharminc.com/press-release/2021/4/5/innovation-pharma-completes-interim-safety-data-reviewdmc-approves-increased-dosing-frequency-in-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients monthly 0.5 2021-04-05 http://www.ipharminc.com/press-release/2021/3/10/innovation-pharmas-covid-19-drug-candidate-brilacidin-ranked-in-top-three-percent-of-compounds-predicted-to-be-most-effective-against-sars-cov-2 monthly 0.5 2021-03-10 http://www.ipharminc.com/press-release/2021/3/5/recruitment-and-enrollment-underway-at-eight-sites-for-innovation-pharmas-phase-2-clinical-trial-of-brilacidin-for-covid-19 monthly 0.5 2021-03-05 http://www.ipharminc.com/press-release/2021/3/2/innovation-pharmaceuticals-announces-publication-of-peer-reviewed-scientific-article-in-the-journal-viruses-on-the-anti-sars-cov-2-properties-of-brilacidin monthly 0.5 2021-03-05 http://www.ipharminc.com/press-release/2021/2/26/innovation-pharma-provides-study-details-for-ongoing-phase-2-clinical-trial-of-brilacidin-in-hospitalized-covid-19-patients monthly 0.5 2021-02-26 http://www.ipharminc.com/press-release/2021/1/29/innovation-pharmaceuticals-phase-2-clinical-trial-of-brilacidin-for-treating-covid-19-scheduled-to-begin-next-week monthly 0.5 2021-01-29 http://www.ipharminc.com/press-release/2021/1/14/innovation-pharmaceuticals-brilacidin-for-the-treatment-of-covid-19-receives-fda-fast-track-designation monthly 0.5 2021-01-14 http://www.ipharminc.com/press-release/2020/12/21/fda-grants-ind-approval-for-phase-2-clinical-trial-of-innovation-pharmaceuticals-brilacidin-for-treating-covid-19 monthly 0.5 2020-12-21 http://www.ipharminc.com/press-release/2020/11/30/innovation-pharmaceuticals-covid-19-clinical-trial-to-support-additional-development-of-brilacidin-as-a-pan-coronavirus-therapeutic monthly 0.5 2020-11-30 http://www.ipharminc.com/press-release/2020/11/15/innovation-pharmaceuticals-announces-overseas-regulatory-filing-submitted-for-covid-19-clinical-study monthly 0.5 2020-11-16 http://www.ipharminc.com/press-release/2020/11/2/innovation-pharmaceuticals-receives-pre-ind-response-from-fda-on-covid-19-trial monthly 0.5 2020-11-02 http://www.ipharminc.com/press-release/2020/10/30/innovation-pharmaceuticals-and-george-mason-university-announce-public-release-of-laboratory-testing-results-demonstrating-brilacidins-covid-19-treatment-potential monthly 0.5 2020-10-30 http://www.ipharminc.com/press-release/2020/10/2/innovation-pharmaceuticals-announces-pre-ind-meeting-request-granted-by-fda-for-the-study-of-brilacidin-for-the-treatment-of-covid-19 monthly 0.5 2020-10-02 http://www.ipharminc.com/press-release/2020/9/15/laboratory-testing-of-brilacidin-for-covid-19-in-combination-with-remdesivir-reduces-viral-load-by-nearly-100-percent monthly 0.5 2020-09-15 http://www.ipharminc.com/press-release/2020/8/26/dr-william-f-degrado-a-discoverer-of-brilacidin-joins-innovation-pharmaceuticals-as-scientific-advisor monthly 0.5 2020-08-26 http://www.ipharminc.com/press-release/2020/8/24/covid-19-drug-candidate-brilacidin-achieves-a-selectivity-index-among-the-highest-reported-exhibiting-potent-anti-sars-cov-2-activity-at-low-concentrations-clinical-trial-forthcoming monthly 0.5 2020-08-24 http://www.ipharminc.com/press-release/2020/8/4/innovation-pharmaceuticals-and-us-regional-biocontainment-laboratory-nearing-completion-of-brilacidin-anti-sars-cov-2-covid-19-in-vitro-testing monthly 0.5 2020-08-04 http://www.ipharminc.com/press-release/2020/7/22/innovation-pharmaceuticals-grants-licensing-rights-to-fox-chase-chemical-diversity-center-inc-for-antifungal-technology monthly 0.5 2020-07-22 http://www.ipharminc.com/press-release/2020/7/20/innovation-pharmaceuticals-brilacidin-inhibits-novel-coronavirus-covid-19-by-almost-90-at-the-lowest-concentration-tested-to-date-in-a-human-lung-cell-line monthly 0.5 2020-07-20 http://www.ipharminc.com/press-release/2020/7/13/innovation-pharmaceuticals-clinical-trial-testing-of-brilacidin-against-sars-cov-2-covid-19-targeted-to-commence-q4-2020 monthly 0.5 2020-07-13 http://www.ipharminc.com/press-release/2020/7/7/in-vitro-testing-of-innovation-pharmaceuticals-brilacidin-for-covid-19-shows-consistent-anti-sars-cov-2-efficacy-manufacturing-preparation-underway-for-covid-19-clinical-trial monthly 0.5 2020-07-07 http://www.ipharminc.com/press-release/2020/6/17/innovation-pharmaceuticals-brilacidin-inhibits-sars-cov-2-covid-19-by-97-percent-in-a-human-lung-cell-line monthly 0.5 2020-06-17 http://www.ipharminc.com/press-release/2020/6/11/innovation-pharmaceuticals-collaborating-with-regional-biocontainment-lab-on-grant-application-to-research-brilacidin-as-a-pan-coronavirus-therapeutic monthly 0.5 2020-06-11 http://www.ipharminc.com/press-release/2020/5/26/innovation-pharmaceuticals-receives-data-from-public-health-research-institute-showing-brilacidin-inhibits-sars-cov-2-covid-19-in-a-human-cell-line monthly 0.5 2020-05-26 http://www.ipharminc.com/press-release/2020/5/19/innovation-pharmaceuticals-brilacidin-reduces-viral-titer-of-sars-cov-2-covid-19-by-75-percent-after-only-1-hour-of-preincubation-in-in-vitro-study-at-bsl-3-facility monthly 0.5 2020-05-19 http://www.ipharminc.com/press-release/2020/5/5/inhibitory-effect-of-innovation-pharmaceuticals-brilacidin-on-sars-cov-2-covid-19-in-primary-human-immune-cells-to-be-studied-at-leading-public-health-research-institute monthly 0.5 2020-05-05 http://www.ipharminc.com/press-release/2020/4/27/innovation-pharmaceuticals-informed-next-phase-of-brilacidin-coronavirus-covid-19-testing-to-begin-week-of-may-4 monthly 0.5 2020-04-27 http://www.ipharminc.com/press-release/2020/4/20/screening-of-11552-compounds-identifies-innovation-pharmaceuticals-brilacidin-as-one-of-the-most-promising-potential-inhibitors-of-the-novel-coronavirus monthly 0.5 2020-04-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1587352068527-LDVBAV9OPYHX7W79FRYT/BRI+In+Silico+Drug+Repurposing+Article+Shortlist+of+Promising+Drugs+Image.JPG Press Releases - Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus http://www.ipharminc.com/press-release/2020/4/6/innovation-pharmaceuticals-in-discussions-to-advance-brilacidin-into-human-trials-against-covid-19 monthly 0.5 2020-04-06 http://www.ipharminc.com/press-release/2020/4/1/innovation-pharmaceuticals-receives-data-supporting-brilacidins-direct-inhibition-of-sars-cov-2-the-novel-coronavirus-responsible-for-covid-19 monthly 0.5 2020-04-01 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1585740133034-GSA3P4NW4AOS4W7Y0WGC/BRI+Efficacy+anti+SARS+CoV+2+figure+1.JPG Press Releases - Innovation Pharmaceuticals Receives Data Supporting Brilacidin’s Direct Inhibition of SARS-CoV-2, the Novel Coronavirus Responsible for COVID-19 http://www.ipharminc.com/press-release/2020/3/17/innovation-pharmaceuticals-brilacidin-to-be-researched-as-possible-novel-coronavirus-covid-19-vaccine-brilacidin-now-being-tested-as-drug-and-vaccine-at-different-institutions monthly 0.5 2020-03-17 http://www.ipharminc.com/press-release/2020/3/12/innovation-pharmaceuticals-announces-testing-procedures-of-brilacidin-against-coronavirus-covid-19 monthly 0.5 2020-03-12 http://www.ipharminc.com/press-release/2020/3/10/us-regional-biocontainment-lab-to-begin-testing-of-brilacidin-against-coronavirus-covid-19-next-week monthly 0.5 2020-03-10 http://www.ipharminc.com/press-release/2020/3/9/innovation-pharmaceuticals-brilacidin-received-by-us-regional-biocontainment-laboratory-testing-against-coronavirus-covid-19 monthly 0.5 2020-03-09 http://www.ipharminc.com/press-release/2020/3/6/innovation-pharmaceuticals-signs-second-mta-to-explore-brilacidin-as-coronavirus-covid-19-treatment monthly 0.5 2020-03-06 http://www.ipharminc.com/press-release/2020/3/5/innovation-pharmaceuticals-plans-for-phase-2-trial-of-new-treatment-for-ulcerative-colitis monthly 0.5 2020-03-05 http://www.ipharminc.com/press-release/2020/3/2/innovation-pharmaceuticals-provides-scientific-rationale-and-clinical-development-perspectives-for-brilacidin-as-a-potential-novel-coronavirus-covid-19-treatment monthly 0.5 2020-03-02 http://www.ipharminc.com/press-release/2020/2/27/innovation-pharmaceuticals-to-ship-brilacidin-to-us-regional-biocontainment-laboratory-for-research-against-coronavirus-covid-19 monthly 0.5 2020-02-27 http://www.ipharminc.com/press-release/2020/2/24/innovation-pharmaceuticals-submits-material-transfer-agreement-to-study-lead-defensin-mimetic-brilacidin-for-coronavirus-covid-19 monthly 0.5 2020-02-24 http://www.ipharminc.com/press-release/2020/2/18/innovation-pharmaceuticals-exploring-lead-defensin-mimetic-drug-candidate-brilacidin-as-potential-novel-coronavirus-treatment monthly 0.5 2020-02-18 http://www.ipharminc.com/press-release/2020/2/13/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin monthly 0.5 2020-02-13 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1581598320310-TWVN9FMDHPVPEHV6EIYF/BDD+Gamma+S+images+series.png Press Releases - Innovation Pharmaceuticals Phase 1 Trial of Brilacidin for Ulcerative Colitis Meets Primary Endpoints; Positive Topline Results of Oral Brilacidin http://www.ipharminc.com/press-release/2020/1/29/innovation-pharmaceuticals-further-engages-locust-walk-to-lead-out-licensing-negotiations-for-rights-to-phase-3-ready-oral-mucositis-drug-candidate monthly 0.5 2020-01-29 http://www.ipharminc.com/press-release/2020/1/24/innovation-pharmaceuticals-completes-dosing-in-phase-1-trial-for-new-oral-ulcerative-colitis-drug monthly 0.5 2020-01-24 http://www.ipharminc.com/press-release/2020/1/17/innovation-pharmaceuticals-announces-dose-escalation monthly 0.5 2020-01-17 http://www.ipharminc.com/press-release/2020/1/16/innovation-pharmaceuticals-announces-dosing-of-first-cohort-in-phase-1-trial-of-oral-brilacidin-in-ulcerative-colitis-program-topline-results-anticipated-early-q1-2020 monthly 0.5 2020-01-16 http://www.ipharminc.com/press-release/2019/12/26/innovation-pharmaceuticals-patient-screening-for-phase-1-trial-of-oral-brilacidin-in-ulcerative-colitis-program-on-track-for-early-january monthly 0.5 2019-12-26 http://www.ipharminc.com/press-release/2019/12/13/innovation-pharmaceuticals-granted-regulatory-approval-to-start-phase-1-trial-of-oral-brilacidin-in-ulcerative-colitis-program monthly 0.5 2019-12-13 http://www.ipharminc.com/press-release/2019/12/10/innovation-pharmaceuticals-provides-update-on-clinical-trials-and-revenue-potential-of-brilacidin-in-inflammatory-bowel-diseases monthly 0.5 2019-12-10 http://www.ipharminc.com/press-release/2019/11/25/innovation-pharmaceuticals-and-fda-agree-to-waive-initial-pediatric-study-plan-requirement-regarding-brilacidin-for-the-prevention-of-oral-mucositis monthly 0.5 2019-11-25 http://www.ipharminc.com/press-release/2019/11/13/innovation-pharmaceuticals-oral-cancer-on-the-rise-company-offers-perspectives-on-opportunity-of-brilacidin-for-the-prevention-of-oral-mucositis monthly 0.5 2019-11-13 http://www.ipharminc.com/press-release/2019/10/14/innovation-pharmaceuticals-partnering-provides-momentum-for-inflammatory-bowel-disease-programs-targeting-a-substantial-and-prized-market-with-a-large-unmet-patient-need monthly 0.5 2019-10-14 http://www.ipharminc.com/press-release/2019/10/3/innovation-pharmaceuticals-clinical-trial-of-oral-brilacidin-in-ulcerative-colitis-program-expected-to-commence-in-december-top-line-data-in-q1-2020 monthly 0.5 2019-10-03 http://www.ipharminc.com/press-release/2019/9/30/innovation-pharmaceuticals-engages-locust-walk-a-global-life-sciences-transaction-firm monthly 0.5 2019-09-30 http://www.ipharminc.com/press-release/2019/9/16/innovation-pharmaceuticals-announces-successful-formulation-of-oral-brilacidin-tablets-upcoming-clinical-trial-to-target-delivery-to-the-colon monthly 0.5 2019-09-16 http://www.ipharminc.com/press-release/2019/9/10/innovation-pharmaceuticals-plans-for-clinical-trial-of-oral-brilacidin-for-ulcerative-colitis-program-in-4th-quarter-2019 monthly 0.5 2019-09-10 http://www.ipharminc.com/press-release/2019/7/29/innovation-pharmaceuticals-provides-corporate-update-highlighting-clinical-pipeline-progress-and-business-development-activities monthly 0.5 2019-07-29 http://www.ipharminc.com/press-release/2019/7/22/innovation-pharmaceuticals-announces-license-agreement-with-alfasigma-spa-for-the-development-and-commercialization-of-brilacidin-in-ulcerative-proctitis-ulcerative-proctosigmoiditis monthly 0.5 2019-07-22 http://www.ipharminc.com/press-release/2019/6/6/innovation-pharmaceuticals-signs-agreement-for-advanced-oral-tablet-technology-in-treating-inflammatory-bowel-disease monthly 0.5 2019-06-06 http://www.ipharminc.com/press-release/2019/5/29/innovation-pharmaceuticals-to-attend-2019-bio-international-convention-june-3-6 monthly 0.5 2019-05-29 http://www.ipharminc.com/press-release/2019/5/21/innovation-pharmaceuticals-at-digestive-disease-week-conference monthly 0.5 2019-05-21 http://www.ipharminc.com/press-release/2019/5/16/innovation-pharmaceuticals-announces-non-binding-term-sheet-signed-with-global-pharmaceutical-company-to-develop-and-commercialize-brilacidin-for-ulcerative-proctitisproctosigmoiditis monthly 0.5 2019-05-16 http://www.ipharminc.com/press-release/2019/5/1/innovation-pharmaceuticals-receives-fda-end-of-phase-2-meeting-minutes monthly 0.5 2019-05-01 http://www.ipharminc.com/press-release/2019/4/23/innovation-pharmaceuticals-jama-article-reinforces-need-for-novel-oral-mucositis-treatments-in-supportive-cancer-care monthly 0.5 2019-04-23 http://www.ipharminc.com/press-release/2019/3/28/innovation-pharmaceuticals-european-subsidiary-ipix-pharma-ltd-granted-meeting-with-european-medicines-agency-ema-to-discuss-international-phase-3-brilacidin-oral-mucositis-program monthly 0.5 2019-03-28 http://www.ipharminc.com/press-release/2019/3/14/innovation-pharmaceuticals-requesting-european-medicines-agency-ema-input-for-international-phase-3-brilacidin-oral-mucositis-program monthly 0.5 2019-03-14 http://www.ipharminc.com/press-release/2019/2/26/innovation-pharmaceuticals-forms-irish-subsidiary-to-facilitate-international-development-of-clinical-pipeline monthly 0.5 2019-02-26 http://www.ipharminc.com/press-release/2019/2/19/innovation-pharmaceuticals-receives-new-patent-for-compounds-for-use-in-treatment-of-oral-mucositis monthly 0.5 2019-02-19 http://www.ipharminc.com/press-release/2019/1/31/innovation-pharmaceuticals-establishing-european-subsidiary-ceo-increases-equity-stake-in-ipix monthly 0.5 2019-01-31 http://www.ipharminc.com/press-release/2019/1/22/innovation-pharmaceuticals-announces-clinical-development-plans-for-oral-brilacidin-for-inflammatory-bowel-disease monthly 0.5 2019-01-22 http://www.ipharminc.com/press-release/2019/1/14/innovation-pharmaceuticals-completes-gastric-fluid-testing-of-brilacidin-supporting-development-of-an-oral-dosage-form-to-treat-inflammatory-bowel-disease monthly 0.5 2019-01-14 http://www.ipharminc.com/press-release/2019/1/8/published-studies-confirm-cisplatin-remains-preferred-chemotherapy-component-in-head-and-neck-cancer-treatment monthly 0.5 2019-01-08 http://www.ipharminc.com/press-release/2019/1/2/innovation-pharmaceuticals-receives-new-brilacidin-patent-further-expanding-intellectual-property-estate monthly 0.5 2019-01-02 http://www.ipharminc.com/press-release/2018/12/17/innovation-pharmaceuticals-completes-end-of-phase-2-meeting-with-fda-brilacidin-oral-rinse-to-advance-into-phase-3-clinical-trials-for-prevention-of-severe-oral-mucositis monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2018/11/13/innovation-pharmaceuticals-presenting-brilacidin-for-inflammatory-bowel-disease-at-ibd-innovate-2018-conference-hosted-by-the-crohns-amp-colitis-foundation monthly 0.5 2018-11-13 http://www.ipharminc.com/press-release/2018/11/1/innovation-pharmaceuticals-expands-brilacidin-patent-portfolio monthly 0.5 2018-11-01 http://www.ipharminc.com/press-release/2018/10/24/innovation-pharmaceuticals-granted-end-of-phase-2-meeting monthly 0.5 2018-10-24 http://www.ipharminc.com/press-release/2018/10/12/innovation-pharmaceuticals-brilacidin-as-a-novel-inhibitor-of-phosphodiesterase-4-pde4-supports-its-potential-to-treat-autoimmune-and-inflammatory-diseases monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2018/10/9/innovation-pharmaceuticals-secures-up-to-10-million-in-additional-financing-to-advance-clinical-pipeline monthly 0.5 2018-10-09 http://www.ipharminc.com/press-release/2018/9/24/innovation-pharmaceuticals-provides-a-comparative-perspective-on-brilacidins-potential-to-unlock-the-oral-mucositis-market-pharma-industry-attacks-severe-pain-and-suffering-due-to-canc-be9z7 monthly 0.5 2018-09-24 http://www.ipharminc.com/press-release/2018/9/05/innovation-pharmaceuticals-to-present-brilacidin-for-inflammatory-bowel-disease-at-inaugural-ibd-innovate-2018-conference-hosted-by-the-crohns-colitis-foundation monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2018/7/17/innovation-pharmaceuticals-signs-drug-product-manufacturing-contract-with-corerx-to-formulate-and-package-brilacidin-for-oral-mucositis-in-sachet-form monthly 0.5 2018-07-17 http://www.ipharminc.com/press-release/2018/6/28/innovation-pharmaceuticals-announces-7-million-milestone-funding-agreement-with-aspire-capital monthly 0.5 2018-06-28 http://www.ipharminc.com/press-release/2018/5/9/innovation-pharmaceuticals-concludes-data-analysis-of-its-phase-2-clinical-trial-for-severe-oral-mucositis-in-head-and-neck-cancer-positioning-to-fill-a-substantial-void-in-supportive-c-ysxm8 monthly 0.5 2018-05-09 http://www.ipharminc.com/press-release/2018/4/23/innovation-pharmaceuticals-signs-drug-supply-contract-with-evonik-to-bulk-produce-commercial-grade-brilacidin monthly 0.5 2018-04-23 http://www.ipharminc.com/press-release/2018/4/16/innovation-pharmaceuticals-data-from-phase-2-brilacidin-oral-mucositis-om-trial-in-head-and-neck-cancer-show-notable-reductions-in-median-duration-of-severe-om-and-in-number-of-unplann-fw3g6 monthly 0.5 2018-04-16 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1523889545954-4IGUZ4EWJG4AD4IGP9PC/SOM+Duration+Table.JPG Press Releases - Innovation Pharmaceuticals Data from Phase 2 Brilacidin Oral Mucositis (OM) Trial in Head and Neck Cancer Show Notable Reductions in Median Duration of Severe OM and in Number of Unplanned Visits... http://www.ipharminc.com/press-release/2018/4/9/innovation-pharmaceuticals-phase-2-oral-mucositis-trial-additional-data-show-brilacidin-om-demonstrated-a-significant-reduction-in-the-incidence-of-severe-oral-mucositis monthly 0.5 2018-04-09 http://www.ipharminc.com/press-release/2018/3/15/innovation-pharmaceuticals-views-brilacidin-om-as-clearly-differentiated-compared-to-limited-competition-for-preventing-severe-oral-mucositis monthly 0.5 2018-03-15 http://www.ipharminc.com/press-release/2018/1/16/innovation-pharmaceuticals-presents-at-2018-biotech-conference-oral-mucositis-drug-candidate-garners-exceptional-interest-after-successful-phase-2-trial monthly 0.5 2018-01-16 http://www.ipharminc.com/press-release/2018/1/3/innovation-pharmaceuticals-brilacidin-meets-key-secondary-endpoint-in-phase-2-trial-delays-onset-of-severe-oral-mucositis-som monthly 0.5 2018-01-04 http://www.ipharminc.com/press-release/2017/12/18/innovation-pharmaceuticals-brilacidin-oral-mucositis-program-moving-forward-based-upon-positive-anchoring-phase-2-results-and-increased-brilacidin-franchise-value monthly 0.5 2017-12-18 http://www.ipharminc.com/press-release/2017/12/12/innovation-pharmaceuticals-granted-european-patent-for-brilacidin-in-the-prevention-of-oral-mucositis monthly 0.5 2017-12-12 http://www.ipharminc.com/press-release/2017/12/11/innovation-pharmaceuticals-reports-positive-topline-results-from-phase-2-placebo-controlled-trial-of-brilacidin-for-the-prevention-of-oral-mucositis-in-head-and-neck-cancer-patients monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/11/16/innovation-pharmaceuticals-offers-perspectives-on-brilacidin-as-a-potential-preventative-treatment-for-oral-mucositis-in-head-and-neck-cancer-patients monthly 0.5 2017-11-16 http://www.ipharminc.com/press-release/2017/10/25/jk5qd8ltvc4ed00ekrbqwbej1vz0x1 monthly 0.5 2017-10-26 http://www.ipharminc.com/press-release/2017/10/24/innovation-pharmaceuticals-provides-development-update-on-brilacidin-for-inflammatory-bowel-disease monthly 0.5 2017-10-24 http://www.ipharminc.com/press-release/2017/10/18/innovation-pharmaceuticals-to-complete-phase-2-trial-of-brilacidin-for-oral-mucositis-in-cancer-patients monthly 0.5 2017-10-18 http://www.ipharminc.com/press-release/2017/10/2/final-patient-completes-treatment-in-innovation-pharmaceuticals-phase-2-trial-of-brilacidin-for-oral-mucositis monthly 0.5 2017-10-02 http://www.ipharminc.com/press-release/2017/9/11/innovation-pharmaceuticals-secures-new-30-million-common-stock-purchase-agreement monthly 0.5 2017-09-11 http://www.ipharminc.com/press-release/2017/8/6/innovation-pharmaceuticals-completes-patient-enrollment-in-phase-2-study-of-brilacidin-for-the-prevention-of-severe-oral-mucositis monthly 0.5 2017-08-15 http://www.ipharminc.com/press-release/2017/7/13/innovation-pharmaceuticals-phase-2-poc-trial-for-inflammatory-bowel-disease-achieves-induction-of-remission-in-a-majority-of-patients-treated-with-brilacidin monthly 0.5 2017-07-13 http://www.ipharminc.com/press-release/2017/6/24/innovation-pharmaceuticals-completes-treatments-in-phase-2-poc-trial-for-induction-of-remission-in-inflammatory-bowel-disease-topline-results-with-endoscopic-response-to-be-presented monthly 0.5 2020-08-23 http://www.ipharminc.com/press-release/2017/6/9/innovation-pharmaceuticals-name-and-ticker-change-effective-replay-of-shareholder-conference-call-available monthly 0.5 2017-06-09 http://www.ipharminc.com/press-release/2017/6/2/cellceutix-announces-company-name-change-to-innovation-pharmaceuticals-inc monthly 0.5 2017-06-07 http://www.ipharminc.com/press-release/2017/5/15/cellceutix-completes-patient-enrollment-of-final-cohort-in-phase-2-trial-of-brilacidin-for-inflammatory-bowel-disease-topline-results-anticipated-in-july monthly 0.5 2017-06-24 http://www.ipharminc.com/press-release/2017/5/10/cellceutix-provides-corporate-update-significant-milestones-ahead-as-multiple-mid-phase-clinical-trials-set-to-conclude monthly 0.5 2017-05-10 http://www.ipharminc.com/press-release/2017/4/19/cellceutix-announces-details-for-upcoming-shareholder-and-investor-presentations monthly 0.5 2017-04-19 http://www.ipharminc.com/press-release/2017/4/8/cellceutix-ceo-discusses-brilacidin-following-interim-trial-results-exceeding-expectations-for-treating-oral-mucositis-and-inflammatory-bowel-disease monthly 0.5 2017-04-10 http://www.ipharminc.com/press-release/2017/3/27/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative--jtrsf monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/3/19/cellceutix-releases-favorable-topline-findings-as-part-of-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-the-treatment-of-inflammatory-bowel-disease monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/3/15/cellceutixs-phase-2-drug-candidate-brilacidin-emerging-as-a-potential-novel-non-biologic-therapy-in-treating-inflammatory-bowel-disease monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/3/8/cellceutix-releases-preliminary-efficacy-and-safety-data-in-interim-analysis-of-first-two-cohorts-in-phase-2-trial-of-brilacidin-for-the-induction-of-remission-of-mild-to-moderate-ulcer-txkdw monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/2/22/cellceutix-phase-2-brilacidin-trial-progresses-to-highest-dose-cohort-for-the-induction-of-remission-of-mild-to-moderate-ulcerative-colitis monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/2/15/y3616250ilexnq8enkoy8lelciljue monthly 0.5 2017-06-24 http://www.ipharminc.com/press-release/2017/1/22/cellceutixs-brilacidin-demonstrates-promise-in-treating-ulcerative-colitis-supported-by-endoscopic-assessment-patient-reported-outcomes monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/1/17/cellceutix-strongly-denounces-criminal-enterprise-mako-research-who-published-fake-news-full-of-lies-and-innuendo monthly 0.5 2017-01-18 http://www.ipharminc.com/press-release/2017/1/17/cellceutix-completes-enrollment-in-second-of-three-planned-cohorts-in-phase-2-clinical-trial-of-brilacidin-for-inflammatory-bowel-disease monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2017/1/4/cellceutix-to-present-at-biotech-showcase-2017-brilacidin-for-oral-mucositis-nears-interim-results monthly 0.5 2017-02-16 http://www.ipharminc.com/press-release/2016/12/6/cellceutix-phase-2-trial-dose-escalates-in-2nd-cohort-for-brilacidin-as-a-novel-anti-inflammatory-drug-candidate-for-ulcerative-colitis monthly 0.5 2022-09-29 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-provides-corporate-update-and-reports-q1-fiscal-2017-financial-results monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/14/cellceutix-announces-business-update-call-at-10am-eastern-on-november-15 monthly 0.5 2016-12-15 http://www.ipharminc.com/press-release/2016/10/27/cellceutix-novel-anti-inflammatory-phase-2-drug-candidate-brilacidin-builds-momentum-across-multiple-clinical-indications monthly 0.5 2022-09-03 http://www.ipharminc.com/press-release/2016/10/27/cellceutix-phase-2-trial-initial-data-shows-potential-of-brilacidin-as-a-novel-anti-inflammatory-drug-candidate-for-induction-of-remission-of-mild-to-moderate-ulcerative-colitis monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/10/27/cellceutix-announces-appointment-of-vice-president-for-regulatory-affairs monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/10/27/cellceutix-further-expands-its-senior-managment-team-with-the-addition-of-an-industry-veteran monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/10/27/cellceutix-expedites-phase-2-trial-of-brilacidin-om-for-oral-mucositis monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/10/cellceutix-receives-update-on-first-patient-enrollment-in-phase-2-proof-of-concept-study-of-brilacidin-for-ulcerative-proctitis monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/10/cellceutix-corporation-announces-industry-veteran-arthur-p-bertolino-md-phd-mba-joins-company-as-president-and-chief-medical-officer monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/10/cellceutix-starts-phase-2-trial-of-brilacidin-as-a-novel-therapy-for-ulcerative-proctitis monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/10/cellceutix-announces-dismissal-of-class-action-lawsuit-filed-by-rosen-law-firm monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/12/cellceutix-receives-preliminary-approval-for-clinical-trial-of-brilacidin-for-ulcerative-proctitis monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/12/cellceutix-corporation-welcomes-dr-stephen-t-sonis-to-its-scientific-advisory-board monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/12/cellceutix-submits-special-protocol-assessment-request-to-fda-for-phase-3-clinical-trial-of-brilacidin-for-absssi monthly 0.5 2016-11-15 http://www.ipharminc.com/press-release/2016/11/12/cellceutix-files-motion-to-dismiss-complaint-filed-by-the-rosen-law-firm monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/brilacidin-lyophilized-as-cellceutix-prepares-to-bring-first-new-class-of-antibiotic-to-phase-3-trials-in-more-than-20-years monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/12/cellceutix-invites-all-to-attend-its-live-webcast-of-companys-presentation-at-biotech-showcase-2016 monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-lab-testing-of-brilacidin-for-planned-phase-3-trial-for-acute-bacterial-skin-and-skin-structure-infections monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-retains-former-durata-executive-ronald-trust-as-regulatory-affairs-consultant monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/fda-grants-fast-track-designation-to-cellceutixs-brilacidin-om-for-oral-mucositis monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-provides-brilacidin-update-new-class-of-antibiotics-to-enter-phase-3 monthly 0.5 2016-11-30 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-date-for-annual-meeting monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-provides-update-on-its-phase-3-preparations-for-absssi monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-retains-ashcroft-law-firm-seeks-withdrawal-of-complaint monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-brilacidin-data-to-be-presented-by-icpd-at-the-joint-55th-interscience-conference-on-antimicrobial-agents-chemotherapy-icaac monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2017/2/7/cellceutix-thank-you monthly 0.5 2017-02-07 http://www.ipharminc.com/press-release/2017/2/7/ieoasadelja0cm1122682nwus4f5n7 monthly 0.5 2017-02-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-ongoing-enrollment-of-phase-2-trial-of-brilacidin-for-oral-mucositis monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-to-start-brilacidin-phase-3-program-in-absssi monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/enrollment-in-cellceutix-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis-expanding-to-additional-centers monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/enrollment-begins-in-cellceutix-phase-2-trial-of-brilacidin-om-to-prevent-oral-mucositis-in-patients-undergoing-chemoradiation monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-results-for-quarter-ended-march-31-2015-enrollment-for-oral-mucositis-studies-to-begin-this-month monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-selects-independent-directors-and-committee-members monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/ff7qf8bgvx0vm1spri1m7tv7ssavaz monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-plans-clinical-trial-in-patients-with-ulcerative-proctitis monthly 0.5 2021-01-08 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-phase-2b-clinical-trial-of-brilacidin-accepted-for-oral-presentation-at-the-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-releases-confidence-interval-statistics-showing-clinical-success-rates-for-brilacidin-in-treatment-of-absssi monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-adds-dr-daniel-jorgensen-as-chief-medical-officer monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-positive-results-of-brilacidin-in-microbiological-intent-to-treat-population-in-phase-2b-absssi-trial monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/patient-enrollment-in-cellceutix-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis-targeted-to-begin-in-december-2014 monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutixs-new-chief-operating-officer-dr-james-alexander-addresses-shareholders monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-investigational-new-drug-ind-application-becomes-effective-selects-first-site-for-phase-2-clinical-trial-of-new-treatment-for-oral-mucositis monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/usmu4z7it1wpp93uku5cwsl2hvngp6 monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-appoints-dr-barry-schecter-to-board-of-directors-as-company-focuses-on-meeting-requirements-of-stock-exchange-uplisting monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-enrollment-in-phase-2b-clinical-trial-of-brilacidin-for-acute-bacterial-skin-and-skin-structure-infections-absssi monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-prepares-for-phase-2-clinical-trial-of-brilacidin-om-for-oral-mucositis monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-believes-brilacidin-on-track-to-help-us-avoid-falling-into-post-antibiotic-era monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-breakthrough-in-the-formulation-of-novel-antibiotic-brlaicidin-plans-studies-to-treat-diabetic-foot-ulcers monthly 0.5 2016-11-16 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-brilacidin-absssi-trial-gets-positive-review-by-data-safety-monitoring-board monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-plans-for-entry-into-diabetic-foot-wound-and-ulcer-market monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/study-shows-cellceutix-antibiotic-active-against-drug-resistant-superbug-klebsiella-pneumoniae monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-comments-on-positive-fda-advisory-vote-for-dalbavancin-and-tedizolid monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-20-percent-enrollment-completed-in-phase-2b-trial-of-brilacidin-as-short-course-therapy-for-absssi monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-reports-14-acute-bacterial-skin-and-skin-structure-infections-absssi-patients-treated-in-phase-2b-clinical-trial monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceuitx-expands-to-gram-negative-bacterial-infections monthly 0.5 2016-11-23 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-enrolls-first-patients-in-phase-2b-absssi-clinical-trial monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-selects-dr-reddys-laboratories-for-formulation-of-brilacidin-for-opthalmic-and-otitis-infections monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-files-with-fda-for-phase-2b-clinical-trial-of-novel-antibiotic-brilacidin-enrollment-of-patients-expected-to-start-mid-february monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-sees-increased-valuation-potential-for-its-novel-antibiotic-brilacidin monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-corporation-to-present-at-biotech-showcase monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-files-orphan-drug-designation-application-for-brilacidin-for-oral-mucositis-with-us-fda monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-to-pursue-significant-conjunctivitis-and-keratitis-ocular-markets-with-novel-antibiotic-brilacidin monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-enters-into-new-20-million-common-stock-purchase-agreement-with-aspire-capital-fund-llc monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-structures-for-significant-growth-in-upcoming-year monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-drug-brilacidin-may-be-the-key-antibiotic-on-the-horizon-for-serious-skin-infections-plans-to-start-phase-2b-study-in-january-2014 monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-antibiotic-brilacidin-chosen-by-elsevier-as-top-project-to-watch-in-infectious-disease monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-plans-phase-2b-trial-of-new-antibiotic-reports-fifth-cohort-complete-in-novel-cancer-drug-clinical-trial monthly 0.5 2016-11-17 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-completes-acquistion-of-polymedix-assets monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/16/cellceutix-acquires-polymedix-assets-from-bankruptcy-court-gains-ownership-of-two-clinical-stage-drugs-multiple-compounds-and-equipment-assets monthly 0.5 2016-12-07 http://www.ipharminc.com/press-release/2016/11/18/cellceutix-announces-settlement-with-former-ceo monthly 0.5 2016-11-18 http://www.ipharminc.com/press-release/2016/11/18/cellceutix-announces-departure-of-george-w-evans-as-ceo monthly 0.5 2016-11-18 http://www.ipharminc.com/press-release/2016/11/18/cellceutix-autism-research-demonstrates-increase-in-serotonin-levels-in-three-areas-of-the-brain monthly 0.5 2022-09-28 http://www.ipharminc.com/press-release/2016/11/18/new-autism-drug-research-by-cellceutix-on-compound-km-391-results-in-significant-behavioral-changes monthly 0.5 2022-09-28 http://www.ipharminc.com/press-release/2016/11/17/cellceutix-announces-positive-results-with-autism-compound-km-391-showing-significant-improvements-in-key-parameters-in-animal-studies monthly 0.5 2022-09-03 http://www.ipharminc.com/press-release/category/Corporate monthly 0.5 http://www.ipharminc.com/press-release/category/Brilacidin monthly 0.5 http://www.ipharminc.com/new-blog daily 0.75 2022-07-21 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477576152696-RQM6WW3G071L14FNAJ6L/image-asset.jpeg Updates http://www.ipharminc.com/new-blog/2022/7/22/brilacidin-revenue-opportunity-in-oral-mucositis monthly 0.5 2022-07-22 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1658431075102-KMLM04P54QA5YQDGR2UT/BRI+OM+Rev+%231.jpg Updates - Brilacidin Revenue Opportunity in Oral Mucositis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1658431123535-R4ENX3QY6FLPFU5Y5TKE/BRI+OM+Rev+%232.jpg Updates - Brilacidin Revenue Opportunity in Oral Mucositis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1658431143709-4QF5SR72GZK3VEF41A03/BRI+OM+Rev+%233.jpg Updates - Brilacidin Revenue Opportunity in Oral Mucositis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1658431167045-LZ87ORFDVWWN1Z9X76CG/BRI+OM+Rev+%234.jpg Updates - Brilacidin Revenue Opportunity in Oral Mucositis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1658431196134-7VZXWZYSMDI5CJGS1G5N/BRI+OM+Rev+%235.jpg Updates - Brilacidin Revenue Opportunity in Oral Mucositis - Make it stand out Whatever it is, the way you tell your story online can make all the difference. http://www.ipharminc.com/new-blog/2022/3/15/scientific-advisor-william-f-degrado-gives-keynote-lecture-at-2021-faraday-discussion-also-co-awarded-the-2020-john-scott-medal monthly 0.5 2022-03-15 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1638891570044-FAKSFS9FE20N84H31FND/Faraday+%231.PNG Updates - Scientific Advisor William F. DeGrado Gives Keynote Lecture at 2021 Faraday Discussion, also Co-Awarded the 2020 John Scott Medal - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1638891597230-KD4V2I2RFB8TUKYZIG88/Faraday+%232.PNG Updates - Scientific Advisor William F. DeGrado Gives Keynote Lecture at 2021 Faraday Discussion, also Co-Awarded the 2020 John Scott Medal - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1638891614882-LXE1MA4241QK74NFK132/Faraday+%233.PNG Updates - Scientific Advisor William F. DeGrado Gives Keynote Lecture at 2021 Faraday Discussion, also Co-Awarded the 2020 John Scott Medal - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1638891633747-N8P0JZB4Z7ORI2U6UU6X/Faraday+%234.PNG Updates - Scientific Advisor William F. DeGrado Gives Keynote Lecture at 2021 Faraday Discussion, also Co-Awarded the 2020 John Scott Medal - Make it stand out Whatever it is, the way you tell your story online can make all the difference. http://www.ipharminc.com/new-blog/2022/1/25/shareholder-alert-upcoming-update-on-brilacidin-in-covid-19 monthly 0.5 2022-01-25 http://www.ipharminc.com/new-blog/2021/7/16/shareholder-alert-covid-19-trial-update-upcoming-antiviral-conferences-july-16-2021 monthly 0.5 2021-07-16 http://www.ipharminc.com/new-blog/2021/6/7/shareholder-alert-recent-journal-article-discusses-antiviral-peptides-potential-against-sars-cov-2 monthly 0.5 2021-06-08 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1623095651786-8W8GIKIUSSJ1EZBT2OLC/Viruses+Compelling+Evidence+for+the+Activity+of+Antiviral+Peptides+Against+SARS-CoV-2+%231.PNG Updates - Recent Journal Article Discusses Antiviral Peptides Potential Against SARS-CoV-2 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. http://www.ipharminc.com/new-blog/2021/5/5/journal-article-on-defensins-highlights-brilacidins-potential-as-a-broad-spectrum-antiviral monthly 0.5 2021-05-05 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1620178846066-FRELI665VW6V2EU0KQKG/Defensin+Antiviral+%231.PNG Updates - Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1620179206297-H9H5LHZHTHOY7QFQB9HM/Defensin+Antiviral+%232.PNG Updates - Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1620179271288-WCH7DDNBIU88P2NX0E9Q/Defensin+Antiviral+%233.PNG Updates - Journal Article on Defensins Highlights Brilacidin’s Potential as a Broad Spectrum Antiviral http://www.ipharminc.com/new-blog/2021/3/10/machine-learning-model-supports-brilacidins-antiviral-properties monthly 0.5 2021-03-11 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1615150729145-M59FRYGQY38RPL6A9012/Machine+Learning+Abstract+%231.PNG Updates - Machine Learning Model Supports Brilacidin’s Antiviral Properties https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1615150766337-ROEM3SPSRXUJ1X8QA2Y1/Machine+Learning+Schematic+%232.PNG Updates - Machine Learning Model Supports Brilacidin’s Antiviral Properties https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1615150797599-MFO3L1NUKL0SWDDQUJ27/Machine+Learning+Schematic+%233.PNG Updates - Machine Learning Model Supports Brilacidin’s Antiviral Properties https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1615150862870-6TXJBNFEFETCNNPQUV8R/Machine+Learning+Top+47+Compounds+%234.PNG Updates - Machine Learning Model Supports Brilacidin’s Antiviral Properties http://www.ipharminc.com/new-blog/2021/1/20/the-rise-of-coronavirus-variants-early-signs-of-immune-escape monthly 0.5 2021-03-15 http://www.ipharminc.com/new-blog/2020/10/30/preprint-brilacidin-a-covid-19-drug-candidate-exhibits-potent-in-vitro-antiviral-activity-against-sars-cov-2 monthly 0.5 2020-11-04 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1604002351965-5485J34OUWAYQ8AT7VL5/Bri+paper+title+1.JPG Updates - Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1604002393971-6IBTBCSDMO3EVOZYMIMB/Bri+paper+abstract+2.JPG Updates - Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1604004858852-RXIZID6JOB1VV015JO31/Bri+paper+Fig+1.JPG Updates - Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1604003088855-AP5Q11NA8XOSUAM1GLX5/Bri+paper+Fig+4.JPG Updates - Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1604005023073-96KIZOCUTOU7IIJT2W0E/Bri+paper+Fig+5b-c.JPG Updates - Preprint: Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2 http://www.ipharminc.com/new-blog/2020/10/2/research-article-shows-sars-cov-2-suppresses-defensins-supports-brilacidins-treatment-potential-for-covid-19 monthly 0.5 2020-10-02 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1601657958497-UIRLRK9JN10VLPCGL6M5/Defensin+Downregulation+Table.JPG Updates - Research Article Shows SARS-CoV-2 Suppresses Defensins; Supports Brilacidin’s Treatment Potential for COVID-19 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1601658022131-LVFQI7754KOOZ2BEZ7LW/Defensin+Downregulation+Figure.JPG Updates - Research Article Shows SARS-CoV-2 Suppresses Defensins; Supports Brilacidin’s Treatment Potential for COVID-19 Source: “Downregulation of Defensin genes in SARS-CoV-2 infection.” (pdf) Mohammed M Idris, Sarena Banu, Archana B Siva, Ramakrishnan Nagaraj. medRxiv 2020.09.21.20195537. http://www.ipharminc.com/new-blog/2020/9/21/shareholder-alert-scientists-advance-on-one-of-technologys-holy-grails-new-yorker-article-on-de-novo-protein-design monthly 0.5 2020-09-22 http://www.ipharminc.com/new-blog/2020/7/20/covid-19-is-the-worst-yet-to-come monthly 0.5 2020-07-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1595108885149-BW40H04J1SQRGYCIKTQW/image-asset.jpeg Updates - COVID-19: Is the Worst Yet to Come? Source: Su X, et al. “Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells.” Front. Microbiol. 25 May 2020; also see: Xiu S, et al. “Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities.” J. Med. Chem. (June 15, 2020); Tiwari V, et al. “Discovering Small-Molecule Therapeutics Against SARS-CoV-2.” Drug Discovery Today (June 20, 2020). http://www.ipharminc.com/new-blog/2020/5/21/brilacidin-for-covid-19-proposed-targets-and-mechanisms-of-action-against-sars-cov-2 monthly 0.5 2020-05-27 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1590195438510-5K8E0N2FSDLXAEUHO3CN/BRI+Multimodal+MOA+SARS+CoV+2+graphic+fv.JPG Updates - Brilacidin for COVID-19: Proposed Targets and Mechanisms of Action Against SARS-CoV-2 Adapted from: Sorbera LA, et al. “Taking Aim at Fast-Moving Target: Targets to Watch for SARS-CoV-2 and COVID-19” (pdf). Drugs of the Future, 45(4):1-6 (Advanced Publication). Clarivate Analytics. 1 See May 19, 2020 Press Release 2 See May 26, 2020 Press Release; Wang C, et al (2020); Whisenant J and K Burgess (2020); and Kit O and Y Kit (2020) 3 See Cavasotto C and JD Filippo (2020); Pant S, et al (2020) 4 Data on file 5 Date on file Forward-Looking Statements: This shareholder alert contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the future execution of a definitive agreement with a global pharmaceutical company and the anticipated terms thereof, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Company’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Company’s licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Company’s compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation. http://www.ipharminc.com/new-blog/2020/5/3/the-novel-coronavirus-master-of-disguise monthly 0.5 2020-05-03 http://www.ipharminc.com/new-blog/2020/3/11/defensins-as-vaccines monthly 0.5 2020-03-12 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583974751837-8Q3VXKB120U2ZK5YHA48/Def+as+Vax+1.jpeg Updates - Defensins as Vaccines Source: Park MS, et al. “Towards the Application of Human Defensins at Antivirals.” Biomol Ther(Seoul). 2018 May 1;26(3):242-254. doi: 10.4062/biomolther.2017.172. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583974809379-FJZB2UWJVWWVKBPF28D9/Def+as+Vax+2.jpeg Updates - Defensins as Vaccines Source: Kim, J, et al. “Human β-defensin 2 Plays a Regulatory Role in Innate Antiviral Immunity and Is Capable of Potentiating the Induction of Antigen-Specific Immunity.” Virol J. 2018; 15: 124. Published online 2018 Aug 8. doi: 10.1186/s12985-018-1035-2 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583974858483-9GA2SQJ59QJJTDL3ONK3/Def+as+Vax+3.jpeg Updates - Defensins as Vaccines Source: Biragyn, A. “Defensins—Non-Antibiotic Use for Vaccine Development.” Current Protein and Peptide Science, Volume 6, Number 1, 2005, pp. 53-60(8). http://www.ipharminc.com/new-blog/2020/3/6/review-article-supports-brilacidins-therapeutic-potential-as-a-defensin-mimetic-drug-candidate monthly 0.5 2020-03-07 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546335614-O7UDPBPDCWLHC8PQH195/BRI+HDP+rvw+article+topical.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546404427-ET4QME4BZ8QVR1FUXL4E/BRI+HDP+rvw+article+systemic.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546448631-BMOBO8TN5VAP5MEQQBZY/BRI+HDP+rvw+article+abstract.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546481491-M1RSR2EWXNY0V0T5258S/BRI+HDP+rvw+article+structure+activity.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546554021-NIDUP3J4QRZ0ZQ0SFEJ0/BRI+HDP+rvw+article+antibacterial.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583546595437-R00Z6NCP6X77Q1OJYRSU/BRI+HDP+rvw+article+immunomodulatory.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583547189268-RKVPJ1DOISGYYUP9G5IU/BRI+HDP+rvw+article+antiviral.JPG Updates - Review Article Supports Brilacidin’s Therapeutic Potential as a Defensin-Mimetic Drug Candidate Mookherjee, N, et al. “Antimicrobial Host Defence Peptides: Functions and Clinical Potential.” Nat Rev Drug Discov. 2020 Feb 27. doi: 10.1038/s41573-019-0058-8. [Epub ahead of print] http://www.ipharminc.com/new-blog/2020/2/28/shareholder-alert-scientific-rationale-for-brilacidin-as-a-potential-novel-coronavirus-covid-19-treatment monthly 0.5 2020-04-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091019361-KAGNKGCDEHFBWIHJC8O9/3.1.2020+BRI+COVID19+1.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091075972-QKLF9VWCN5HGFKNEKA3K/3.1.2020+BRI+COVID19+2.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091111303-CWPCNYOPJGKIOJ9V6V8S/3.1.2020+BRI+COVID19+3.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091176311-D8I3R6T30593Z6MUEAUR/3.1.2020+BRI+COVID19+4.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091248371-TJ51WC2V34CBNVKURFQV/3.1.2020+BRI+COVID19+5.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1583091285643-SVKUGLLRADFQ68WDE0BR/3.1.2020+BRI+COVID19+6.JPG Updates - Shareholder Alert: Scientific Rationale for Brilacidin as a Potential Novel Coronavirus (COVID-19) Treatment http://www.ipharminc.com/new-blog/2020/2/25/shareholder-alert-additional-brilacidin-mta-submitted-to-regional-biocontainment-lab monthly 0.5 2020-02-25 http://www.ipharminc.com/new-blog/2020/2/18/shareholder-alert-defensins-are-conceptually-ideal-for-defense-against-different-viral-infections monthly 0.5 2020-02-18 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1582031368837-143OT6SQTBLAN5VIMY30/Towards+Applications+of+Human+Defensins+as+Antivirals+2018+abstract.JPG Updates - Shareholder Alert: “Defensins are conceptually ideal for defense against different viral infections.” https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1582031790476-SXD0FJLLLF3IDNDLXPOW/Defensins+Antiviral+MOA.jpg Updates - Shareholder Alert: “Defensins are conceptually ideal for defense against different viral infections.” Source: Park MS et al. “Towards the Application of Human Defensins as Antivirals.” Biomol Ther (Seoul). 2018 May 1;26(3):242-254. doi: 10.4062/biomolther.2017.172. http://www.ipharminc.com/new-blog/2020/2/10/shareholder-alert-phase-1-targeted-delivery-topline-results-expected-later-this-week monthly 0.5 2020-02-10 http://www.ipharminc.com/new-blog/2020/1/23/shareholder-alert-innovation-pharmaceuticals-announces-dose-escalation-for-final-cohort monthly 0.5 2020-01-23 http://www.ipharminc.com/new-blog/2020/1/9/shareholder-alert-site-initiation-visit-completed-for-phase-1-clinical-trial-of-brilacidin-for-ulcerative-colitis monthly 0.5 2020-01-09 http://www.ipharminc.com/new-blog/2019/12/4/coverage-indicates-3x-greater-revenue-potential-for-brilacidin-oral-rinse monthly 0.5 2019-12-04 http://www.ipharminc.com/new-blog/2019/11/27/ipix-laser-focused-on-ibd-and-om-as-fastest-path-to-revenue monthly 0.5 2019-11-27 http://www.ipharminc.com/new-blog/2019/10/8/literature-supporting-therapeutic-potential-of-host-defense-peptide-protein-hdp-based-drug-candidates-such-as-brilacidin monthly 0.5 2022-09-29 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1570403562424-4EUWOGJ2FZ4QNKAHNMAI/HDP+M+Blog+Image+1.jpg Updates - Literature Supporting Therapeutic Potential of Host Defense Peptide/Protein (HDP)-Based Drug Candidates Such as Brilacidin https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1570403668588-Z7HSA8N9DD05SWIL4NXP/HDP+M+Blog+Image+3.png Updates - Literature Supporting Therapeutic Potential of Host Defense Peptide/Protein (HDP)-Based Drug Candidates Such as Brilacidin https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1570403731912-2WE4JECM3P57U1XALGLZ/HDP+M+Blog+Image+4.png Updates - Literature Supporting Therapeutic Potential of Host Defense Peptide/Protein (HDP)-Based Drug Candidates Such as Brilacidin http://www.ipharminc.com/new-blog/2019/4/9/brilacidin-competitive-positioning-market-opportunity-for-oral-mucositis monthly 0.5 2019-04-09 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1554822808279-3JMEKNTLY5Z7SP1IH34H/OM+Apr+2019+Blog+Graphic+1.JPG Updates - Brilacidin – Competitive Positioning, Market Opportunity for Oral Mucositis https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1554822840294-COGOSMTIJ94XUPXQD3RH/OM+Apr+2019+Blog+Graphic+2.JPG Updates - Brilacidin – Competitive Positioning, Market Opportunity for Oral Mucositis https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1554822873593-II8J5BH2G07DOCJJ8892/OM+Apr+2019+Blog+Graphic+3.JPG Updates - Brilacidin – Competitive Positioning, Market Opportunity for Oral Mucositis http://www.ipharminc.com/new-blog/2018/11/22/innovation-pharmaceuticals-wishes-shareholders-a-happy-thanksgiving monthly 0.5 2018-11-22 http://www.ipharminc.com/new-blog/2018/9/24/brilacidin-for-oral-mucositis-at-a-glance-comparative-data-presentation-with-other-investigational-om-drugs monthly 0.5 2018-09-24 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1537552869918-5BKQ4Z8Y9E24YRO6IYQ5/IPIX+BRI+OM+Comparative+Table.JPG Updates - Brilacidin for Oral Mucositis: At-a-Glance Comparative Data Presentation with Other Investigational OM Drugs Source references provide full details. Data summarized in the table is condensed from source references, with assumptions and simplifications made as required. Sources: Brilacidin data (Innovation Pharmaceuticals Press Releases: April 9, 2018; December 11, 2017; IPI CTIX-BRI-205 Clinical Study Report, on file); GC4419 data (Anderson et al 2018 [i]; Anderson et al 2018 [ii]; Galera Therapeutics Press Release); SGX942 data (Kudrimoti et al 2016, Supplemental Table 1); Clonidine Lauriad® data (Onxeo/clinicaltrials.gov results 2017); Palifermin data (Le et al 2011; Henke et al 2011). http://www.ipharminc.com/new-blog/2018/8/2/a-slow-motion-epidemic-treating-inflammatory-bowel-disease-in-the-21st-century monthly 0.5 2018-08-04 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1532975349909-66NSJ59DJJM04O9AU9J9/IBD+Crohns+UC.JPG Updates - A Slow-Motion Epidemic: Treating Inflammatory Bowel Disease in the 21st Century Source: Eisenstein, M. “Biology: A Slow-Motion Epidemic.” Nature. Volume 540, pages S98–S99 (22 December 2016). https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1532975395127-YEW89K9SUX4R6M9CSR95/IBD+Cascade.JPG Updates - A Slow-Motion Epidemic: Treating Inflammatory Bowel Disease in the 21st Century Source: Eisenstein, M. “Biology: A Slow-Motion Epidemic.” Nature. Volume 540, pages S98–S99 (22 December 2016). https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1532975430877-57K3WZ48QU2V7PZLK7PB/IBD+Prevalance.JPG Updates - A Slow-Motion Epidemic: Treating Inflammatory Bowel Disease in the 21st Century Source: Eisenstein, M. “Biology: A Slow-Motion Epidemic.” Nature. Volume 540, pages S98–S99 (22 December 2016). http://www.ipharminc.com/new-blog/2018/5/4/brilacidin-om-in-the-news-oral-mucositis-market-untappedframed-as-blue-sky-opportunity monthly 0.5 2018-05-04 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1525367151318-3AQGJ4BWJAO0LUETBBPI/Baystreet+Screenshot.JPG Updates - Brilacidin-OM in the News: Oral Mucositis Market Untapped—Framed as “Blue Sky” Opportunity Source: http://www.baystreet.ca/articles/stockstowatch/38594/Taking-a-Page-from-Mercks-Gardasil-and-Glaxos-Requip-These-Small-Companies-Look-to-Cement-Riches-for-Shareholders-in-New-Category-of-Oral-Mucositis http://www.ipharminc.com/new-blog/2018/3/7/brilacidin-as-a-novel-late-stage-antibiotic-drug-candidate monthly 0.5 2020-05-15 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1505925609847-YQXDYLUZMV02920KVILE/WHO+Report+Brilacidin+4.PNG Updates - Brilacidin as a Novel Late-Stage Antibiotic Drug Candidate Source: http://www.who.int/medicines/news/2017/IAU_AntibacterialAgentsClinicalDevelopment_webfinal_2017_09_19.pdf https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1518559980203-6YS6QU4I2NYY1LCK0XGC/BRI+as+Broad+Spectrum.PNG Updates - Brilacidin as a Novel Late-Stage Antibiotic Drug Candidate “Brilacidin, Host Defense Peptide Mimetic, One of a New Class of Immunomodulatory Agents That Can Target Multiple Disease Indications” (ECCMID 2015) (pdf) https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1518560137394-PS2UML0HN7D7KJVTA1S3/BRI+Ph2b+ABSSSI+Results+w+Images.PNG Updates - Brilacidin as a Novel Late-Stage Antibiotic Drug Candidate Source: “A Randomized, Double-Blind Study Comparing Single-Dose and Short-Course Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin & Skin Structure Infections” (ECCMID 2015) https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1518560340579-NVURKQ6Y7CXN8SUB71NK/PMX+30063+Comp+Positioning.PNG Updates - Brilacidin as a Novel Late-Stage Antibiotic Drug Candidate Source: “Chemical Mimetics of Host Defense Proteins” (ICAAC 2011; Company Presentation, 2012) (PDF); note: PMX-30063 is the former name assigned to Brilacidin. http://www.ipharminc.com/new-blog/2017/12/11/brilacidin-om-called-a-top-contender-in-oral-mucositis-market monthly 0.5 2017-12-11 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1512569937039-272JQ9OMLCCNCSUKS2BP/Baystreet+2.PNG Updates - Brilacidin-OM Called a “Top Contender” in Oral Mucositis Market http://www.ipharminc.com/new-blog/2017/11/21/brilacidin-as-a-successful-example-of-de-novo-drug-design monthly 0.5 2020-03-29 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1509372786698-AXCW0RSO8NJ3CYZYA7XQ/DeGrado+Peptide+Science.PNG Updates - Brilacidin as a Successful Example of De Novo Drug Design Source: “Big Bad Bill is sweet William now.” Joel Schneider. Editorial. Peptide Science. Vol 104, Issue 4 (July 2015), pages v-vi. http://www.ipharminc.com/new-blog/2017/10/24/deficient-defensins-and-missing-mucins-in-the-pathogenesis-of-inflammatory-bowel-disease monthly 0.5 2018-01-22 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1500490852215-STE88A4OAWNW0IB6L08H/Defensins+Mucins+Quotes.PNG Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1500490880348-SJOM63ZOAB1CEK74YDQD/image-asset.jpeg Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1500490906335-E3X2TTL34F90XIL7022C/image-asset.png Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1500490944202-CXGRA0PV3UDP9HN2T2YB/image-asset.png Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1508779393975-9OADWKNMNK2RIBL9M7OS/B+Cytokines.PNG Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1508779416843-7R8NOKLBOD52FHTYJRNA/B+ABX+activity.PNG Updates - Deficient Defensins and Missing Mucins in the Pathogenesis of Inflammatory Bowel Disease Source: “Brilacidin, Host Defense Peptide Mimetic, One of a New Class of Immunomodulatory Agents That Can Target Multiple Disease Indications” (ECCMID 2015) (pdf) http://www.ipharminc.com/new-blog/2017/10/17/the-market-opportunity-in-oral-mucositis monthly 0.5 2017-12-13 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1508263146549-BNXMP7CYZLJP6162YBB7/HNC+Regions.PNG Updates - The Market Opportunity in Oral Mucositis Source: https://www.cancer.gov/types/head-and-neck/head-neck-fact-sheet https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1508263199157-YZ4Q6H15TJLLK57ESII9/HNC+Incidence.PNG Updates - The Market Opportunity in Oral Mucositis Source: “Head and Neck Cancer in India: Global and Regional Trends”; DOI: http://dx.doi.org/10.7314/APJCP.2014.15.2.537 (pdf) https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1513195852284-KASFGQTWJE3B8IA5X4A1/GlobalData+OM.PNG Updates - The Market Opportunity in Oral Mucositis Source: GlobalData https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1513202115085-FZC818NYW77NUX5YZBWP/OM+Risk+Matrix+by+Treatment.PNG Updates - The Market Opportunity in Oral Mucositis Source: https://clinicalgate.com/oral-complications-2/ http://www.ipharminc.com/new-blog/2017/9/25/innovation-anti-fungal-compound-shows-potent-activity-against-multi-drug-resistant-candida-and-new-fungal-superbug monthly 0.5 2017-09-26 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1506346405915-QEC43EVJOVSW35ORXYMY/AntiFungal+Study.PNG Updates - Innovation Anti-Fungal Compound Shows Potent Activity Against Multi-Drug Resistant Candida and New Fungal “Superbug” Source: “Potent In Vitro and In Vivo Antifungal Activity of a Small Molecule Host Defense Peptide Mimic through a Membrane-Active Mechanism.” Scientific Reports 7, Article number: 4353 (2017) https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1506346431702-SYO8F26T40FBXNXOPPOO/Anti+Fungal+Membrane.PNG Updates - Innovation Anti-Fungal Compound Shows Potent Activity Against Multi-Drug Resistant Candida and New Fungal “Superbug” Source: “Potent In Vitro and In Vivo Antifungal Activity of a Small Molecule Host Defense Peptide Mimic through a Membrane-Active Mechanism.” Scientific Reports 7, Article number: 4353 (2017) http://www.ipharminc.com/new-blog/2017/9/11/brilacidin-formulation-work monthly 0.5 2017-12-04 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1495141882715-0MWRK5MMONAQRKO4YDM2/image-asset.png Updates - Brilacidin Formulation Work https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1499879807864-XQZW0VUGA329P5784RMJ/image-asset.png Updates - Brilacidin Formulation Work Source: "Oral Delivery of Macromolecular Drugs: Where We Are After Almost 100 Years of Attempts." Advanced Drug Delivery Reviews. Volume 101, 1 June 2016, Pages 108-121. http://www.ipharminc.com/new-blog/2017/8/7/brilacidin-for-oral-mucositis monthly 0.5 2017-12-14 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1497377783928-RFYMKEA8X7HJXJMCA3WW/image-asset.png Updates - Brilacidin for the Prevention of Severe Oral Mucositis https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1501784594124-9WO4MKTCWJ0GAHKI2J5M/image-asset.png Updates - Brilacidin for the Prevention of Severe Oral Mucositis Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439125/ http://www.ipharminc.com/new-blog/2017/7/13/ulcerative-proctitisulcerative-proctosigmoiditissubstantial-opportunity-exists-for-newer-therapies-like-brilacidin-to-emerge monthly 0.5 2017-11-24 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1499363946258-FSHH78POAJB3YV3H5Y42/testtest Updates - Ulcerative Proctitis / Ulcerative Proctosigmoiditis — Opportunity for Newer Therapies Like Brilacidin to Emerge Source:https://www.ibdrelief.com/ https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1499363964199-4Z21OJ5TZ18DQEY64KGP/image-asset.gif Updates - Ulcerative Proctitis / Ulcerative Proctosigmoiditis — Opportunity for Newer Therapies Like Brilacidin to Emerge Source: “Conquering the Clinical Challenges of IBD: Optimizing Anti-TNF-Alpha Therapy: Ulcerative Colitis: The Role of Biologic Therapy.” Presented by William J. Sandborn. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1499955184291-HEO71LKGG842209L4TU5/image-asset.png Updates - Ulcerative Proctitis / Ulcerative Proctosigmoiditis — Opportunity for Newer Therapies Like Brilacidin to Emerge Source: "Budenoside Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis." Gastroenterology. 2015 Apr;148(4):740-750.e2. doi: 10.1053/j.gastro.2015.01.037. Epub 2015 Jan 30. http://www.ipharminc.com/new-blog/2017/7/3/growing-interest-in-novel-non-biologic-treatments-for-inflammatory-bowel-disease monthly 0.5 2017-12-22 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1495227522015-GV22IV8ECK56H59OAJMW/image-asset.png Updates - Growing Interest in Novel Treatments for Inflammatory Bowel Disease https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498856568686-UOO621HL9CT6JC7OCE8P/image-asset.png Updates - Growing Interest in Novel Treatments for Inflammatory Bowel Disease http://www.ipharminc.com/new-blog/2017/7/1/the-role-of-defensins-in-innate-immunity-and-the-host-defense-response monthly 0.5 2018-01-11 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498854703961-Y3Z5FRC9PI60R6IEA2MB/image-asset.png Updates - The Role of Defensins in Innate Immunity and the Host Defense Response https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498854723283-Z5SBEOC3EH4O58O3V1W2/image-asset.png Updates - The Role of Defensins in Innate Immunity and the Host Defense Response https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498857807263-3UJQI91OYMD2RL4FY7PW/image-asset.png Updates - The Role of Defensins in Innate Immunity and the Host Defense Response http://www.ipharminc.com/new-blog/2017/6/1/brilacidins-mechanism-of-action-targeting-the-il-17-pathway monthly 0.5 2017-11-09 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498479092205-JVP2BTY84LJXR3AGB3UT/image-asset.png Updates - Brilacidin’s Mechanism of Action; Targeting the IL-17 Pathway https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498479334896-7MDQCTARBK05RDDIZ2YW/image-asset.png Updates - Brilacidin’s Mechanism of Action; Targeting the IL-17 Pathway https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1498488499719-PKB2IABZ4JQQC57NEZJP/image-asset.png Updates - Brilacidin’s Mechanism of Action; Targeting the IL-17 Pathway http://www.ipharminc.com/new-blog/2017/6/14/brilacidin-for-ibda-promising-novel-non-corticosteroid-non-biologic-drug-candidate monthly 0.5 2017-06-23 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1495044056748-8124S1JBWQDPAZ3R0MNG/image-asset.png Updates - Brilacidin for IBD—A Promising Novel, Non-Corticosteroid, Non-Biologic Drug Candidate http://www.ipharminc.com/new-blog/2017/6/2/dr-francis-farraye-on-the-use-of-endoscopy-in-ibd monthly 0.5 2017-06-23 http://www.ipharminc.com/new-blog/2017/5/17/on-the-unmet-need-in-oral-mucositis-and-brilacidin-as-a-promising-one-of-a-kind-treatment monthly 0.5 2017-08-06 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1495037917347-JTUO66SP9BXC3GQ7V6FD/image-asset.png Updates - On the Unmet Medical Need in Oral Mucositis: Brilacidin as a Potential First-in-Class Preventative Treatment http://www.ipharminc.com/new-blog/2017/2/2/ibd-inpatient-costs-skyrocketing-1 monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1486074855326-R86UE6FT0VMO1YY66AUR/image-asset.png Updates - IBD Inpatient Costs Skyrocketing http://www.ipharminc.com/new-blog/2017/2/2/endoscopic-remission-in-the-treatment-of-ulcerative-colitis monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1486060300011-F5LE0D6DPP9D8SV0T3H7/image-asset.png Updates - Endoscopic Remission in the Treatment of Ulcerative Colitis Source: http://www.fda.gov/downloads/Drugs/Guidances/UCM515143.pdf http://www.ipharminc.com/new-blog/2016/10/5/therapeutic-potential-of-host-defense-protein-hdp-mimetics-1 monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1478572470829-6KB2QRKGCWBJZI2O2BLU/image-asset.png Updates - Clinical Literature Supporting the Therapeutic Potential of Brilacidin and Host Defense Protein (HDP)-Mimetics http://www.ipharminc.com/new-blog/2017/1/6/bloomberg-biotech-deals-expected-to-bounce-in-2017 monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1484140090841-RRVQU1NMW8IFKEMY50V2/image-asset.png Updates - Biotech Deals Expected to Bounce in 2017 Source: https://www.bloomberg.com/gadfly/articles/2017-01-03/biotech-m-a-in-2017-a-new-hope https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1484140272622-61O6JZ7H5AFSA94ZPS2O/image-asset.png Updates - Biotech Deals Expected to Bounce in 2017 http://www.ipharminc.com/new-blog/2016/10/5/signs-of-big-pharma-getting-back-into-the-antibiotics-business-1 monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1478572722972-D8PQ99HE5R0CQ32P7V5O/image-asset.png Updates - Signs of Big Pharma Getting Back into the Antibiotics Business http://www.ipharminc.com/new-blog/2016/11/14/rise-of-the-superbugresistance-to-antibiotics-a-worldwide-crisis-1 monthly 0.5 2017-07-10 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1479153372921-N1GKF8SDF07GHNZ0M9EK/image-asset.png Updates - Rise of the "Superbug"—Resistance to Antibiotics a Worldwide Crisis http://www.ipharminc.com/new-blog/category/Corporate monthly 0.5 http://www.ipharminc.com/new-blog/category/Brilacidin monthly 0.5 http://www.ipharminc.com/image-selections daily 0.75 2016-10-26 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832845352-NWEHG2H9JJ7X9ZMYAPA1/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832845352-NWEHG2H9JJ7X9ZMYAPA1/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832904583-368797RBRM5OFAHM7W5F/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832913879-URH1ZWV6UDVCPZ0TCQND/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832928006-H9TL5TCZ2CMGX0YSMUS6/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475832943124-2MSRLIYIDBMHFZ2WUTKL/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833034200-KOCEQWHHKBYAE5XC1395/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833096209-WL9W67PT301HA1RRWO02/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833163306-3LZFXWXA5EAYW4V9F4YX/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833198350-SMWJDN5RHNQUGR2C4QIN/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833253597-AO0WIQ24KJKXPQG7K56S/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833268023-M5IX47EN2YLKA01M6RXA/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833296428-TYIFMDFQV1ELSFQ6YN00/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833401054-GE4JH2NQDRFJO47X1MFD/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833414554-Q7765ROFD0B2SZMRH6XJ/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833526597-OR2KI90FY2IE9COUBFVG/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476337844388-NHOCM2C19ZP65BIDE795/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336376733-HRRNPC9K4GXTFCI4ISWZ/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833580181-9TQ6IA3RBM98D3QFDYY7/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833808371-G0IMBHT4NY6WHEVO9BGG/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475833819218-IO2GZ2OKPQ75DKCCAN2J/image-asset.jpeg image selections https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476337424880-FW4CQ02EDY1D538O277X/image-asset.jpeg image selections http://www.ipharminc.com/investor-faq daily 0.75 2016-10-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476951727589-24OC0QOYNOSKGXDVVSEI/image-asset.jpeg Investor FAQ http://www.ipharminc.com/investor-faq/2016/10/20/where-is-cellceutix-headquartered monthly 0.5 2020-01-01 http://www.ipharminc.com/investor-faq/2016/10/20/where-is-cellceutix-incorporated monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/when-is-cellceutixs-fiscal-year-end monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/who-is-cellceutixs-independent-registered-accounting-firm monthly 0.5 2018-12-29 http://www.ipharminc.com/investor-faq/2016/10/20/who-is-cellceutixs-legal-counsel monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/on-which-exchange-is-cellceutix-listed monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/what-is-cellceutixs-ticker-symbol monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/does-cellceutix-pay-dividends monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/who-is-cellceutixs-transfer-agent monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/how-can-i-replace-my-lost-stock-certificates monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/what-is-the-cusip-number-of-cellceutixs-common-stock monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/how-can-i-get-a-copy-of-cellceutixs-sec-and-regulatory-filings-and-where-can-i-download-and-view-quarterly-and-annual-reports monthly 0.5 2017-06-23 http://www.ipharminc.com/investor-faq/2016/10/20/how-can-i-apply-for-a-job-at-cellceutix monthly 0.5 2017-12-01 http://www.ipharminc.com/investor-faq/2016/10/20/how-can-i-contact-cellceutix-with-additional-questions monthly 0.5 2017-12-01 http://www.ipharminc.com/new-financials daily 0.75 2016-10-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477317006558-AP5EKSSNIWL999CNIHBJ/download.jpeg New Financials http://www.ipharminc.com/new-financials/2016/10/20/10-q-4 monthly 0.5 2016-10-23 http://www.ipharminc.com/new-financials/2016/10/20/10-q-3 monthly 0.5 2016-10-23 http://www.ipharminc.com/new-financials/2016/10/20/10-q-2 monthly 0.5 2016-10-23 http://www.ipharminc.com/new-financials/2016/10/20/10-q-1 monthly 0.5 2016-10-23 http://www.ipharminc.com/new-financials/2016/10/20/10-q monthly 0.5 2016-10-23 http://www.ipharminc.com/new-financials/category/10-C monthly 0.5 http://www.ipharminc.com/new-financials/category/10-B monthly 0.5 http://www.ipharminc.com/new-financials/category/10-A monthly 0.5 http://www.ipharminc.com/multimedia-audio-1 daily 0.75 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/rodman-renshaw-annual-global-investment-conference monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/biotech-showcase-2014 monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/rodman-henshaw-annual-global-investment-conference monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/biotech-showcase-2015 monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/25th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid2015-brilacidin-poster monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/understanding-qidp-and-other-21st-century-incentives-for-developing-and-marketing-anti-infective-medicinesdr-daniel-jorgensen monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-audio-1/2016/10/25/ld-microjune-2016 monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-video-1 daily 0.75 2016-10-26 http://www.ipharminc.com/multimedia-video-1/2016/10/25/elsevier-therapeutic-area-partnership-tap monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-posters-1 daily 0.75 2016-10-26 http://www.ipharminc.com/multimedia-posters-1/2016/10/25/5-joint-55thinterscience-conference-on-antimicrobial-agents-chemotherapy-and-28thinternational-congress-of-chemotherapy-icaac monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-posters-1/2016/10/25/9-25th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid2015-oral-mucositis-poster monthly 0.5 2016-10-26 http://www.ipharminc.com/multimedia-posters-1/2016/10/25/14a-c-brilacidin-pk-pd-data-presented-at-the-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2013-posters monthly 0.5 2016-10-26 http://www.ipharminc.com/new-events-and-presentations daily 0.75 2023-03-14 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1480548329351-A178KZY2JZPRGRCQCV24/image-asset.jpeg Events and Presentations http://www.ipharminc.com/new-events-and-presentations/2023/3/8/16th-annual-european-conference-on-fungal-genetics monthly 0.5 2023-03-14 http://www.ipharminc.com/new-events-and-presentations/2023/1/22/2023-gordon-research-conference-on-the-immunology-of-fungal-infections monthly 0.5 2023-03-14 http://www.ipharminc.com/new-events-and-presentations/2022/11/15/2022-chemical-and-biological-defense-science-amp-technology-conference monthly 0.5 2022-11-15 http://www.ipharminc.com/new-events-and-presentations/2022/8/8/2022-military-health-system-research-symposium monthly 0.5 2022-09-14 http://www.ipharminc.com/new-events-and-presentations/2021/8/23/2021-military-health-system-research-symposium monthly 0.5 2022-08-08 http://www.ipharminc.com/new-events-and-presentations/2021/7/21-american-society-of-virology-annual-meeting monthly 0.5 2021-07-22 http://www.ipharminc.com/new-events-and-presentations/2018/11/13/crohns-colitis-foundation-ibd-innovate-2018-conference monthly 0.5 2018-11-13 http://www.ipharminc.com/new-events-and-presentations/2017/11/20/biotech-showcase-2018 monthly 0.5 2018-01-16 http://www.ipharminc.com/new-events-and-presentations/2017/9/8/biocenturys-newsmakers-conference monthly 0.5 2017-09-11 http://www.ipharminc.com/new-events-and-presentations/2017/7/13/drug-discovery-and-therapy-world-congress monthly 0.5 2017-07-20 http://www.ipharminc.com/new-events-and-presentations/2017/6/2/shareholder-and-investor-conference-call monthly 0.5 2017-06-08 http://www.ipharminc.com/new-events-and-presentations/2017/4/19/investor-shareholder-update-april-20-2017 monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/12/5/biotech-showcase-january-2016-details-coming-soon monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/q1-fiscal-2017-update monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/23rd-annual-newsmakers-in-the-biotech-industry-conference-corporate-overview monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/american-society-for-microbiology-microbe-2016-application-of-phamacokinetic-pharmacodynamic-models-for-brilacidin-dose-selection-support-for-patients-with-acute-bacterial-skin-and-skin monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/american-society-for-microbiology-microbe-2016-antifungal-potential-of-peptide-mimetics-in-a-mouse-model-of-invasive-candidiasis monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/ld-micro-corporate-presentation monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/biotech-showcase-corporate-presentation monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/joint-55th-interscience-conference-on-antimicrobial-agents-chemotherapy-and-28th-international-congress-of-chemotherapy-icaac-population-pharmacokinetics-ppk-of-brilacidin-in monthly 0.5 2017-06-02 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/understanding-qidp-and-other-21st-century-incentives-for-developing-and-marketing-anti-infectives-a-new-class-of-antimicrobialsthe-hdp-mimetics monthly 0.5 2016-12-01 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/25th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2015-a-randomized-double-blind-study-comparing-single-dose-and-short-course-brilacidin monthly 0.5 2016-12-01 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/25th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2015-brilacidin-host-defense-peptide-mimetic-one-of-a-new-class-of-immunomodulatory monthly 0.5 2016-12-01 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/25th-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2015-synthetic-novel-host-defense-protein-mimetics-for-the-treatment-of-gram-negative-bacterial-infections monthly 0.5 2016-12-06 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/2013-elsevier-therapeutic-area-partnership-tap-infectious-diseases-top-projects-to-watch monthly 0.5 2017-04-21 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/3rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2013-use-of-pharmacokinetics-pharmacodynamics-and-monte-carlo-simulation-analyses-to-support-brilacidin monthly 0.5 2016-12-06 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/3rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2013-population-pharmacokinetic-analyses-of-brilacidin-using-data-from-patients-with-absssi monthly 0.5 2016-12-01 http://www.ipharminc.com/new-events-and-presentations/2016/11/30/23rd-european-congress-of-clinical-microbiology-and-infectious-diseases-eccmid-2013-pharmacokinetic-pharmacodynamic-analyses-for-efficacy-and-safety-of-brilacidin monthly 0.5 2016-12-01 http://www.ipharminc.com/new-events-and-presentations/category/Corporate monthly 0.5 http://www.ipharminc.com/new-events-and-presentations/category/Brilacidin monthly 0.5 http://www.ipharminc.com/new-press-release daily 0.75 2017-04-03 http://www.ipharminc.com/new-press-release/2017/4/2/cellceutix-aacr-poster-presents-data-supporting-kevetrin-modulation-of-p53-in-multiple-human-ovarian-cancer-cell-lines-and-corresponding-xenograft-tumors monthly 0.5 2017-04-03 http://www.ipharminc.com/new-press-release/2017/3/26/cellceutix-reports-very-encouraging-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-severe-oral-mucositis-om-in-head-and-neck-cancer-patients-high-potential-for-preventative--cyml9 monthly 0.5 2017-03-29 http://www.ipharminc.com/new-press-release/category/Kevetrin monthly 0.5 http://www.ipharminc.com/new-press-release/category/Brilacidin monthly 0.5 http://www.ipharminc.com/ipharma-cover-page daily 0.75 2017-06-23 http://www.ipharminc.com/home-1 daily 1.0 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1585719906414-Q7XDRSSWNS5MG8QI79NQ/image-asset.jpeg Home ADVANCING THE FIGHT AGAINST INFECTIOUS DISEASES Brilacidin—exhibits broad-spectrum antimicrobial properties https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1479879630572-B2YV725NHUW63ZBWMTVI/banner1.jpg Home DEVELOPING INNOVATIVE MEDICAL THERAPIES With multiple potential therapeutic applications https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1479879633352-DQFGUNB783LW3NDAA71H/banner3.jpg Home TARGETING ORAL MUCOSITIS A debilitating side-effect of chemoradiation treatment https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1479879633418-VMSFWGPFWWTUIUGESLGA/banner4.jpg Home LEVERAGING THE BODY’S NATURAL DEFENSE Brilacidin—a small molecule mimetic of defensins http://www.ipharminc.com/contact-us daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336538376-C2Q1JWCE9CBS7LLF5O3P/image-asset.jpeg Contact Us http://www.ipharminc.com/overview daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336586923-1IA0MPSJETA7URPO0IXE/image-asset.jpeg Product Overview http://www.ipharminc.com/brilacidin-1 daily 0.75 2023-04-13 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476245584080-AOJDJ1RXC4M4DKDWL88D/image-asset.png Brilacidin https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475219019089-ZCVQ8CBFYWDJDRJD2HZS/image-asset.jpeg Brilacidin http://www.ipharminc.com/stock-information daily 0.75 2017-06-12 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476951941117-1Q7KEV2OAOFYZTCS4ZFH/image-asset.jpeg Stock Information http://www.ipharminc.com/financials-and-filings daily 0.75 2016-10-02 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476951912426-09S4079U1BBVZODF02RV/image-asset.jpeg Financials & Filings http://www.ipharminc.com/corporate-governance daily 0.75 2017-12-26 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476951878920-0PXWBUO0DN6EVKIV066L/image-asset.jpeg Corporate Governance http://www.ipharminc.com/newsroom-1 daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477287990194-HMQH2POI2LO3IUPFGP4S/image-asset.jpeg Welcome http://www.ipharminc.com/about-innovation-pharmaceuticals daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336400099-XHKWJ6WLCERMK6QPWJ6O/image-asset.jpeg Company Background http://www.ipharminc.com/senior-management daily 0.75 2021-03-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336445029-X0H08GPJH8JHM40E7XLJ/image-asset.jpeg Senior Management http://www.ipharminc.com/scientific-advisors daily 0.75 2023-04-17 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336497132-07BBWWZ4AHJNDTVFT24E/image-asset.jpeg Scientific Advisors http://www.ipharminc.com/board-of-directors daily 0.75 2021-03-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336472280-4LV3YU8JLQZYXY6M50PF/image-asset.jpeg Board of Directors http://www.ipharminc.com/collaborations-3 daily 0.75 2019-07-22 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336517368-V8P50XFD3XGVNO2B9I17/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1473834474292-TZ42CP2E7Y2MMB5CLADZ/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475123812196-74LTVINL743RJD2Z2LEF/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1473834338281-U2THEL5XLPNXAPUEKHGS/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475828818398-E1KFEW0RCG2YG6DIZ5EZ/image-asset.jpeg Collaborations http://www.ipharminc.com/stages-of-development daily 0.75 2022-10-04 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336922800-TEJ96FVTAABFA5U5VJW4/image-asset.jpeg Stages of Development https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1664896718768-XIC4QJPI6XA27VJDI0U0/BRI+Pipeline+Oct+2022.jpg Stages of Development - Make it stand out Whatever it is, the way you tell your story online can make all the difference. http://www.ipharminc.com/email-alerts daily 0.75 2021-03-20 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477288107810-S9IPNL1QQU1LDR6J0ITE/image-asset.jpeg Email Alerts http://www.ipharminc.com/term-of-use daily 0.75 2017-06-23 http://www.ipharminc.com/privacy-policy daily 0.75 2017-06-23 http://www.ipharminc.com/site-map daily 0.75 2016-09-28 http://www.ipharminc.com/test-page daily 0.75 2016-09-28 http://www.ipharminc.com/forward-looking-statements daily 0.75 2022-06-22 http://www.ipharminc.com/social-media-disclosure daily 0.75 2016-10-29 http://www.ipharminc.com/events-and-presentations-2-1 daily 0.75 2016-11-18 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477288040938-HLXU34EHDVC7HPM9JDF8/image-asset.jpeg Events & Presentations http://www.ipharminc.com/1024-multimedia daily 0.75 2016-10-29 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1477457402559-JIKBBNZIUVF4YY8I7TOX/image-asset.jpeg Multimedia http://www.ipharminc.com/test-sec-auto-update daily 0.75 2016-11-11 http://www.ipharminc.com/financials daily 0.75 2023-12-14 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1633457527979-CMYX2RL7BIRV2SN38W2U/IPIX+Image+View+2.PNG Financials & Filings http://www.ipharminc.com/expanded-access-and-compassionate-use daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1514305981820-6D2RFI1MGKL647PLCMT0/download.jpeg Expanded Access https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1545973685227-RI5XJYX3JT39SVGDI9S3/newChart-v1.jpg Expanded Access http://www.ipharminc.com/home daily 0.75 2020-04-01 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1563339519916-98AEROWSF9FI6NTLZ02M/iPharma-Banner-v3.jpg Copy of Home Innovation Completes Licensing Agreement with Alfasigma Alfasigma to Develop Brilacidin for UP/UPS in Inflammatory Bowel Disease Learn More https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1585719042683-D86XZGKJD6VI8YQDKZAL/image-asset.jpeg Copy of Home Advancing Brilacidin in the Fight Against COVID-19 Brilacidin being evaluated as a novel Coronavirus therapeutic Learn More http://www.ipharminc.com/collaborations daily 0.75 2022-09-28 https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1476336517368-V8P50XFD3XGVNO2B9I17/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1563428130688-UG03XILO81XT7SCKW7AQ/alfa_logo.jpg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1662212794636-SMK8HYXFL54E5QYAMDPV/FCCDC+Logo.jpg Collaborations - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1473834474292-TZ42CP2E7Y2MMB5CLADZ/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475123812196-74LTVINL743RJD2Z2LEF/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1473834338281-U2THEL5XLPNXAPUEKHGS/image-asset.jpeg Collaborations https://images.squarespace-cdn.com/content/v1/5715352e20c647639137f992/1475828818398-E1KFEW0RCG2YG6DIZ5EZ/image-asset.jpeg Collaborations